Pfizer and BioNTech Receive Positive CHMP Opinion for Conversion of COMIRNATY® Conditional Marketing Authorization to Full Marketing Authorization in…

NEW YORK and MAINZ, GERMANY, September 16, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended converting the conditional Marketing Authorization (cMA) for COMIRNATY® [COVID-19 Vaccine (nucleoside modified)] to standard (also referred to as “full”) Marketing Authorization (MA) for all authorized indications and formulations. The European Commission (EC) will review the CHMP recommendation and is soon expected to make a final decision.

Read more here:
Pfizer and BioNTech Receive Positive CHMP Opinion for Conversion of COMIRNATY® Conditional Marketing Authorization to Full Marketing Authorization in...

ORYZON to Present Preliminary Blinded Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder

MADRID, Spain and BOSTON, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today presents initial preliminary blinded aggregate safety data from its ongoing Phase IIb PORTICO trial, investigating vafidemstat in Borderline Personality Disorder (BDP), in a oral communication at the 10th European Conference on Mental Health (ECMH), being held in Lisbon (Portugal) on September 13-16.

View original post here:
ORYZON to Present Preliminary Blinded Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder

Wave Life Sciences to Host Analyst and Investor Virtual Event, “Towards the Clinic: Spotlight on RNA Editing for AATD,” on September 28, 2022

Focus on WVE-006, a first-in-class RNA editing development candidate for AATD, and feature AATD expert presentation Focus on WVE-006, a first-in-class RNA editing development candidate for AATD, and feature AATD expert presentation

See the original post:
Wave Life Sciences to Host Analyst and Investor Virtual Event, “Towards the Clinic: Spotlight on RNA Editing for AATD,” on September 28, 2022

Belite Bio Receives Approval of LBS-008 Phase 3 Clinical Trial in China

SAN DIEGO, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases, today announced the approval from the National Medical Products Administration (NMPA) of China to initiate the Phase 3 clinical trial of LBS-008 in adolescent STGD1 in China.

See the original post:
Belite Bio Receives Approval of LBS-008 Phase 3 Clinical Trial in China

Myovant Recognizes Prostate Cancer Awareness Month with Educational Sponsorships and Online Campaign to Encourage Patients to Speak Up, Seek Support…

Peer Video Series Campaign and Educational Sponsorships Spotlight Patient Barriers to Conversations Peer Video Series Campaign and Educational Sponsorships Spotlight Patient Barriers to Conversations

Read more from the original source:
Myovant Recognizes Prostate Cancer Awareness Month with Educational Sponsorships and Online Campaign to Encourage Patients to Speak Up, Seek Support...

Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering

HAYWARD, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced it closed its previously announced underwritten public offering of 29,809,471 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase up to 29,809,471 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) was sold together with one common warrant to purchase one share of common stock at a combined offering price of $0.60. The warrants will be exercisable commencing on the effective date of an increase in our authorized shares of common stock at an exercise price of $0.66 per share of common stock and will expire on the fifth anniversary of such initial exercise date.

Here is the original post:
Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering

ORION CORPORATION: ACQUISITION OF OWN SHARES 16.09.2022

See more here:
ORION CORPORATION: ACQUISITION OF OWN SHARES 16.09.2022

Revolo Biotherapeutics to Participate in the Sachs Associates 22nd Annual Biotech in Europe Forum for Global Partnering and Investment

NEW ORLEANS and LONDON, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that it will be participating in the Sachs Associates 22nd Annual Biotech in Europe Forum for Global Partnering and Investment taking place in Basel, Switzerland from September 21-22.

Follow this link:
Revolo Biotherapeutics to Participate in the Sachs Associates 22nd Annual Biotech in Europe Forum for Global Partnering and Investment

AltruBio President and CEO Judy Chou to Participate at the Longwood Healthcare Leaders Fall Webconference

SAN FRANCISCO, Sept. 16, 2022 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of immunological diseases with high unmet medical needs, today announced that AltruBio President and CEO Dr. Judy Chou will speak on “The Next Wave of Targeted Therapies” at the Longwood Healthcare Leaders Fall Webconference on Wednesday, September 21, 2022.

Read more:
AltruBio President and CEO Judy Chou to Participate at the Longwood Healthcare Leaders Fall Webconference

Larimar Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Option to Purchase Additional Shares

BALA CYNWYD, Pa., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the closing of its previously announced underwritten offering of 25,558,750 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase an additional 3,333,750 shares at the offering price of $3.15 per share. The gross proceeds to Larimar, before deducting the underwriting discounts and commissions and estimated offering expenses, were approximately $80.5 million.

Read the rest here:
Larimar Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Option to Purchase Additional Shares